Wedbush Maintains Outperform on Apogee Therapeutics, Raises Price Target to $135

Benzinga Newsdesk www.benzinga.com Positive 91.3%

Neg 0% Neu 0% Pos 91.3%

Wedbush analyst David Nierengarten maintains Apogee Therapeutics (NASDAQ:APGE) with a Outperform and raises the price target from $120 to $135.